Cancer Imaging System Market, By Imaging Modality, By Application, By End-user, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

Cancer Imaging System Market size was valued at US$ 21,987.24 Million in 2024, expanding at a CAGR of 9.5% from 2025 to 2032.
The Cancer Imaging System market refers to the global industry focused on technologies and equipment used to detect, diagnose, and monitor cancer through medical imaging. These systems include modalities such as MRI (Magnetic Resonance Imaging), CT (Computed Tomography), PET (Positron Emission Tomography), ultrasound, and mammography. Cancer imaging plays a vital role in early detection, staging, treatment planning, and evaluating the effectiveness of therapies. Increasing global cancer prevalence, rising awareness about early diagnosis, and advancements in imaging technologies are key drivers of this market.
Innovations like AI-enhanced image interpretation, hybrid imaging systems, and molecular imaging are improving accuracy and diagnostic capabilities. Governments and health organizations worldwide are investing in cancer screening programs, further fueling demand. Moreover, the growing aging population and lifestyle-related cancer risks contribute to market expansion. However, high equipment costs and limited access in low-income regions remain challenges. Overall, the market is evolving rapidly to support precision oncology and patient-centred care.
Cancer Imaging System Market- Market Dynamics

Radiomics enables personalized cancer imaging by extracting data-driven tumor insights.
A niche driver in the Cancer Imaging System market is the growing use of radiomics for personalized oncology. Radiomics involves extracting large volumes of quantitative data from medical images using advanced algorithms. These data points can reveal tumor characteristics such as shape, texture, and intensity that are not visible to the naked eye. This information helps in assessing tumor heterogeneity, predicting treatment response, and improving prognostic accuracy. As precision medicine advances, radiomics is becoming crucial for tailoring cancer treatment to individual patients.
It offers a non-invasive way to gather tumor biology insights, reducing the need for repeated biopsies. Integration with artificial intelligence enhances its ability to detect patterns and correlations. Radiomics also supports clinical decision-making and speeds up research in cancer therapeutics. Its application is expanding in imaging modalities like CT, MRI, and PET. The increasing focus on data-driven healthcare further strengthens its role. As adoption grows, radiomics is set to significantly impact cancer imaging strategies.
Cancer Imaging System Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.5% over the forecast period (2025-2032)
Based on Imaging Modality segmentation, Magnetic Resonance Imaging (MRI) was predicted to show maximum market share in the year 2024
Based on application segmentation, Breast Cancer was the leading application in 2024
Based on region, North America was the leading revenue generator in 2024
Cancer Imaging System Market- Segmentation Analysis:

The Global Cancer Imaging System Market is segmented on the basis of Imaging Modality, Application, End-user, and Region.
The market is divided into three categories based on Imaging Modality: Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Ultrasound, Mammography, and Others. Magnetic Resonance Imaging (MRI) is the most dominant segment in the Cancer Imaging System market due to its superior soft tissue contrast and ability to provide detailed images without ionizing radiation. MRI is widely used for detecting and staging various cancers, including brain, breast, prostate, and liver cancers.
Its advanced functional imaging techniques, such as diffusion-weighted imaging and spectroscopy, enable better tumor characterization and treatment monitoring. Growing demand for non-invasive and precise diagnostic tools, along with continuous technological advancements, further strengthens MRI’s leading position in this market.
The market is divided into two categories based on application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, and Others. Breast Cancer is the most dominant segment in the Cancer Imaging System market due to its high prevalence and the critical need for early detection and screening. Mammography and MRI are widely used for breast cancer imaging, enabling accurate diagnosis and monitoring.
Government screening programs and growing awareness about breast cancer contribute to increased demand for imaging systems. Additionally, advancements in imaging technology have improved the detection of small tumors, enhancing treatment outcomes. This strong focus on breast cancer drives significant market growth within this segment.
Cancer Imaging System Market- Geographical Insights

North America holds a dominant position in the Cancer Imaging System market, driven by high cancer prevalence, advanced healthcare infrastructure, and strong investment in medical technology. The U.S. leads the region with widespread adoption of advanced imaging modalities and integration of AI in diagnostics. Supportive government initiatives and increasing demand for early detection further boost growth. Canada also contributes to rising cancer screening programs and growing access to modern imaging equipment.
The United States represents the largest market for cancer imaging systems globally, supported by a high incidence of cancer and a well-established healthcare system. The country sees significant investments in diagnostic technologies, with widespread use of MRI, CT, PET, and hybrid imaging for early cancer detection and treatment monitoring. Government initiatives like the Cancer Moonshot and expanded Medicare coverage for screening procedures enhance accessibility to imaging services.
Cancer Imaging System Market- Competitive Landscape:

The competitive landscape of the Cancer Imaging System market is characterized by the presence of several global and regional players offering a wide range of imaging solutions. Industry leaders like GE HealthCare, Siemens Healthineers, and Philips Healthcare dominate with comprehensive imaging portfolios and strong R&D capabilities. These companies focus on innovation, integrating AI, radiomics, and advanced software to improve diagnostic precision. Mid-tier players such as Canon Medical and Fujifilm compete through niche technologies and strategic partnerships. Startups and emerging firms are gaining ground by offering AI-driven imaging solutions tailored for oncology.
The market is highly competitive, with players investing in FDA approvals, collaborations with cancer research institutions, and global expansion. Technological advancements, especially in hybrid imaging and molecular diagnostics, are reshaping market dynamics. Pricing strategies, service offerings, and post-installation support also influence competitive positioning. The push toward personalized medicine and early cancer detection continues to drive innovation and rivalry among key stakeholders.

Recent Developments:

In December 2024, Guardant Health, Inc. announced a partnership with Boehringer Ingelheim to secure regulatory approval and advance the commercialization of the Guardant360 CDx liquid biopsy. This collaboration focuses on utilizing the liquid biopsy as a companion diagnostic (CDx) for zongertinib, a novel covalent tyrosine kinase inhibitor (TKI) that selectively targets HER2 while minimizing effects on the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC).
In November 2024, Danaher Corporation revealed plans to establish two new Centers of Innovation in Diagnostics to drive advancements in precision medicine. The first center, based in Newcastle, UK, is set to open in July and will serve as a collaborative research hub with leading pharmaceutical and academic partners. Operated by Leica Biosystems, a Danaher subsidiary, this facility will become Danaher’s first CLIA CAP-certified laboratory.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CANCER IMAGING SYSTEM MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GE HealthCare
Siemens Healthineers
Philips Healthcare
Canon Medical Systems
Fujifilm Holdings
Hologic Inc.
Bracco Imaging
Carestream Health
Esaote SpA
Shimadzu Corporation
Samsung Medison
United Imaging Healthcare
PerkinElmer Inc.
Agfa-Gevaert Group
Konica Minolta Healthcare
Mindray Medical International
Neusoft Medical Systems
ViewRay Inc.
Hyperfine Inc.
Median Technologies

GLOBAL CANCER IMAGING SYSTEM MARKET, BY IMAGING MODALITY- MARKET ANALYSIS, 2019 - 2032

Magnetic Resonance Imaging (MRI)
Computed Tomography (CT)
Positron Emission Tomography (PET)
Ultrasound
Mammography
Others

GLOBAL CANCER IMAGING SYSTEM MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Others

GLOBAL CANCER IMAGING SYSTEM MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Diagnostic Imaging Centers
Specialty Clinics
Academic and Research Institutes

GLOBAL CANCER IMAGING SYSTEM MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more